東大発新興、次世代遺伝子治療を開発へ　治験29年メド | AN Venture Partners

東大発新興、次世代遺伝子治療を開発へ　治験29年メド

MediaPortfolio Companies

東大発新興、次世代遺伝子治療を開発へ　治験29年メド

February 27, 2024

City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics

Press Release

Portfolio Companies

City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics

Cambridge, Mass., June 19, 2026

Crystalys Therapeutics Advances Phase 3 Trials of Dotinurad for the Treatment of Gout with Dosing of First Patient

Press Release

Portfolio Companies

Crystalys Therapeutics Advances Phase 3 Trials of Dotinurad for the Treatment of Gout with Dosing of First Patient

San Diego, October 21, 2025

Privacy Policy

This website uses Google Analytics cookies for access analysis only. The collected data is used solely for improving the website and is handled appropriately. By clicking "AGREE", you consent to the use of cookies.

Privacy Policy

This website uses Google Analytics cookies for access analysis only. The collected data is used solely for improving the website and is handled appropriately. By clicking "AGREE", you consent to the use of cookies.